130 related articles for article (PubMed ID: 17001081)
1. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
Canela N; Orzáez M; Fucho R; Mateo F; Gutierrez R; Pineda-Lucena A; Bachs O; Pérez-Payá E
J Biol Chem; 2006 Nov; 281(47):35942-53. PubMed ID: 17001081
[TBL] [Abstract][Full Text] [Related]
2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
3. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation.
Gondeau C; Gerbal-Chaloin S; Bello P; Aldrian-Herrada G; Morris MC; Divita G
J Biol Chem; 2005 Apr; 280(14):13793-800. PubMed ID: 15649889
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
5. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
6. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition.
Cheng KY; Noble ME; Skamnaki V; Brown NR; Lowe ED; Kontogiannis L; Shen K; Cole PA; Siligardi G; Johnson LN
J Biol Chem; 2006 Aug; 281(32):23167-79. PubMed ID: 16707497
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the ORC1-Cyclin A association.
Wang B; Song J
Protein Sci; 2019 Sep; 28(9):1727-1733. PubMed ID: 31309634
[TBL] [Abstract][Full Text] [Related]
8. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
9. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
10. Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4.
Warenius HM; Kilburn JD; Essex JW; Maurer RI; Blaydes JP; Agarwala U; Seabra LA
Mol Cancer; 2011 Jun; 10():72. PubMed ID: 21668989
[TBL] [Abstract][Full Text] [Related]
11. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
12. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
13. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
14. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
15. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.
Lowe ED; Tews I; Cheng KY; Brown NR; Gul S; Noble ME; Gamblin SJ; Johnson LN
Biochemistry; 2002 Dec; 41(52):15625-34. PubMed ID: 12501191
[TBL] [Abstract][Full Text] [Related]
16. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.
Clare PM; Poorman RA; Kelley LC; Watenpaugh KD; Bannow CA; Leach KL
J Biol Chem; 2001 Dec; 276(51):48292-9. PubMed ID: 11604388
[TBL] [Abstract][Full Text] [Related]
17. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells.
Jin YH; Yoo KJ; Lee YH; Lee SK
J Biol Chem; 2000 Sep; 275(39):30256-63. PubMed ID: 10884382
[TBL] [Abstract][Full Text] [Related]
18. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
19. Activation mechanism of CDK2: role of cyclin binding versus phosphorylation.
Stevenson LM; Deal MS; Hagopian JC; Lew J
Biochemistry; 2002 Jul; 41(26):8528-34. PubMed ID: 12081504
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
